Imperial Center Family Medicine

JUNE 2, 2025

The liver manufactures new cholesterol molecules and captures excess from circulation for excretion. Contact us today at 919-873-4437 or online to book a consultation. Your digestive system doesn’t just process food; it also influences cholesterol screening levels in your bloodstream.

DO 52

DO Family Medicine Screening Specialization 52

FDA Law

JUNE 28, 2023

If a device manufacturer chooses to use an ASCA-accredited testing laboratory to conduct testing for premarket submissions to the FDA, the device manufacturer includes an ASCA declaration of conformity, an ASCA Summary Test Report and a cover letter that indicates that the submission contains ASCA testing as part of their premarket submission.

IT 52

IT Consulting Manufacturing Provider 52

FDA Law

JANUARY 29, 2023

Evans* — A recent analysis of statistics on FDA’s website, prepared for a presentation at a good manufacturing practices (GMP) conference in San Diego next week, shows a dramatic increase in the percentage of FDA drug manufacturing facility inspections that result in an “Official Action Indicated” classification.

Manufacturing 59

Manufacturing Consulting Government IT 59

My Green Doctor

MAY 3, 2025

The product manufacturers and vendors will need to be active partners as well. The precautionary principle: what is the risk of reusing disposable drops in routine ophthalmology consultations and what are the costs of reducing this risk to zero? There are other steps that clinicians can in their practices and hospitals. Cavanagh, D.,

Medical 52

Medical Supply Chain Hospital Healthcare 52

FDA Law

FEBRUARY 23, 2025

Manufacturers must evaluate device changes in the first instance to determine whether a new 510(k) is needed or, instead, whether documentation of the change and rationale for not seeking 510(k) clearance is sufficient. Manufacturers should, therefore, welcome any additional source of examples of device changes to aid in evaluating their own.

Manufacturing 64

Manufacturing Provider Consulting IT 64

FDA Law

APRIL 22, 2024

While FDA recommended rescheduling to schedule III, we think it more likely that if DEA reschedules marijuana it would be to schedule II because the Single Convention still requires manufacturing quotas for cannabis (which are not required for schedule III substances under the CSA). 811(d) and U.S. Whether DEA believes the U.S.

Manufacturing 59

Manufacturing Consulting IT Individual 59

FDA Law

DECEMBER 16, 2024

The final guidance looks much like the prior draft and is intended to satisfy FDAs obligation to issue final guidance on consultations with persons under section 565(i) of the FD&C Act and also to provide clarity on use of third party emergency use authorization (EUA) review.

Consulting 52

Consulting Manufacturing Utilities Provider 52

FDA Law

JANUARY 4, 2023

Brevig, Senior Regulatory Device and Biologics Expert — On December 7, 2022, FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Tissues and Advanced Therapies (OTAT) held a town hall to answer questions related to cell therapy and tissue-engineered products chemistry, manufacturing, and contr­­ols (CMC).

Manufacturing 59

Manufacturing Engineering Clinic Provider 59

FDA Law

NOVEMBER 20, 2024

Chemical characterization can also be useful in evaluating a change to the materials or manufacturing of a device. By Adrienne R. The main body of the draft guidance provides high-level recommendations, and four appendices provide detailed recommendations for test design.

Provider 59

Provider Medical Manufacturing Consulting 59

FDA Law

JANUARY 5, 2022

Prior to joining HP&M, Adrienne worked as an independent regulatory consultant and consultant with Emergo. As a Principal Medical Device Regulation Expert, Adrienne will continue to provide consulting to medical device and combination product manufacturers. (HP&M) is pleased to announce Adrienne R.

Medical 40

Medical Consulting Engineering Manufacturing 40

FDA Law

JUNE 16, 2023

Kirschenbaum — On May 24, Minnesota enacted the Commerce and Consumer Protection Omnibus Bill, Senate File 2744 ( SF 2744 ), which significantly expands the state’s existing drug pricing activities with serious implications for all drug manufacturers, and particularly generic drug manufacturers. We address each below. Best price?

Manufacturing 45

Manufacturing Provider Consulting IT 45

FDA Law

MAY 30, 2022

Schwartz & David Chesney (DL Chesney Consulting LLC) — Things are getting hectic for those of us who advise clients on FDA inspections: FDA is busy addressing its backlog of foreign and domestic inspections. Farquhar & Mark I. Some companies that have been placed on the Import Alert list pending reinspections may finally find relief.

Manufacturing 52

Manufacturing Clinic Consulting Education 52

FDA Law

JANUARY 5, 2022

Prior to joining HP&M, Adrienne worked as an independent regulatory consultant and consultant with Emergo. As a Principal Medical Device Regulation Expert, Adrienne will continue to provide consulting to medical device and combination product manufacturers. (HP&M) is pleased to announce Adrienne R.

Medical 40

Medical Consulting Engineering Manufacturing 40

FDA Law

AUGUST 23, 2021

Kirschenbaum — On August 6, 2021, the Pharmaceutical Research and Manufacturers of America (PhRMA) announced the release of a revised PhRMA Code on Interactions with Health Care Professionals , which takes effect on January 1, 2022. By McKenzie E. Cato & Alan M.

Specialization 52

Specialization Manufacturing Education Provider 52

FDA Law

FEBRUARY 5, 2024

She also provides consulting services for state licenses, as well as regulatory due diligence concerning licensing requirements, primarily for pharmaceutical manufacturers, wholesale distributers, and pharmacies. Keup has joined the firm to assist attorneys Karla L. Palmer , Larry K. Houck , and Kalie E.

Consulting 45

Consulting Manufacturing Government Provider 45

FDA Law

OCTOBER 10, 2023

In the case of 510(k) Implants indicated for use in pediatric patients, FDA recommends consulting two other guidance documents: Pediatrics Guidance and Extrapolation Guidance. We find that this information is noteworthy for manufacturers to consider.

Manufacturing 45

Manufacturing Engineering Clinic Provider 45

FDA Law

DECEMBER 7, 2023

A regulatory consultant on the panel made a recommendation to FDA that it lean more heavily on Remote Interactive Evaluations (“REIs”) to help alleviate its backlog—of which HPM recently learned the Agency had only conducted 10 in the last 30 months for purposes of drug manufacturing compliance.

Consulting 52

Consulting Manufacturing Provider Government 52

GeriPal

MAY 5, 2022

Think about the last time you attended a talk on communication skills or goals of care discussions. Was there any mention about the impact that hearing loss has in communication or what we should do about it in clinical practice? I’m guessing not. COVID-19, masks, and hearing difficulty: Perspectives of healthcare providers. Alex: (Singing).

IT 102

IT Screening Hospital Clinic 102

FDA Law

APRIL 22, 2025

The stakes are high when a DEA-registered practitioner, pharmacy, distributor, manufacturer, or other registrant receives an Order to Show Cause (or OSC) from DEA. Which option is right for you is a decision that is best made after consulting with experienced counsel. What Is an Order to Show Cause?

Government 52

Government Provider Consulting Manufacturing 52

FDA Law

FEBRUARY 1, 2022

To that end, FDA announced that it would take the public input it has received and form a working group to address efforts to “modernize the Orange Book, improve transparency, and provide useful information to regulated industry and the public” by…considering the comments that it has supposed to have been considering all along.

Provider 52

Provider IT Consulting Manufacturing 52

FDA Law

MARCH 20, 2022

Almost all recalls are conducted on a voluntary basis by the manufacturer. Walsh — All companies dread the logistics, cost, and reputational harm associated with conducting a recall when necessary to remove or correct products in the field. It is critical for firms in a product distribution chain to be “recall ready.””. Product coding (e.g.,

Electronics 40

Electronics Manufacturing Provider IT 40

FDA Law

MAY 20, 2021

Investigators likely consult with DEA headquarters about the registrant’s compliance with required reporting and review its registration category, status, and authorized controlled substances to assess whether it may be conducting unauthorized activities. By Larry K. They ask for the results of any state inspections. Policies and Procedures.

Management 40

Management Consulting Provider Physicals 40

FDA Law

MAY 20, 2021

Investigators likely consult with DEA headquarters about the registrant’s compliance with required reporting and review its registration category, status, and authorized controlled substances to assess whether it may be conducting unauthorized activities. By Larry K. They ask for the results of any state inspections. Policies and Procedures.

Management 40

Management Consulting Provider Physicals 40

FDA Law

SEPTEMBER 20, 2021

When travel restrictions and public health precautions halt facilities inspections, many sponsors are left wondering how FDA will complete pre-approval inspections and meet their products’ respective PDUFA dates. requesting records in lieu of an inspection, use of information shared by trusted foreign regulatory partners).

Patient-Centered 52

Patient-Centered Manufacturing Clinic Provider 52

Physician's Weekly

JUNE 19, 2025

In January of last year, Cole went to a Walgreens in Appleton, Wisconsin, to get refills on the medication he used to control his asthma. He’d been taking it for years, and he expected to pay about seventy bucks. He’d have to pay more than 500 dollars. He left without it. A few days later, he had a massive asthma attack.

Insurance 52

Insurance IT Board-Certified Medical 52

FDA Law

JULY 7, 2024

Laboratories struggling to understand the myriad implications of being regulated as device “manufacturers” were hopeful that additional guidance would shed light on how to apply FDA’s existing medical device regulatory framework to their operations. 803), Reporting of Corrections and Removals (21 C.F.R. § 806) and Complaint Files (21 C.F.R.

Manufacturing 64

Manufacturing Provider Physicals Electronics 64

GeriPal

MAY 8, 2025

We’ll discuss three recent clinical trials involving patients with serious illness, joined by our guests James Downar , Ali John Zarrabi , and Margaret Ross. We begin with a refresher on psilocybinwhat it is, how it might work, what conditions it may help treat (including demoralization), and how its typically administered. It’s there.

Illness 107

Illness IT Patient-Centered Patients 107

FDA Law

MARCH 31, 2025

EO 14215 requires employees of agencies, like the FTC, to consult with the USAG on interpretations of the law and removes any agency authority to advance its own legal positions without consultation. The latest iteration of proposed Section 27 in S. But then come the newly revised penalties provisions: (4) CIVIL ACTION.In Further, S.

Consulting 64

Consulting Manufacturing Referral IT 64

FDA Law

JUNE 26, 2023

Houck — The Drug Enforcement Administration (“DEA”) has designated precursor chemicals, including 4-piperidone just last month, used in the illicit manufacture of controlled substances as List I and II chemicals over the years as “laboratory supplies,” but has never revised or updated its Special Surveillance List. 21 U.S.C. § 21 U.S.C. §

Specialization 53

Specialization Manufacturing PCP PCP 53

FDA Law

APRIL 2, 2025

The latest iteration of proposed Section 27 in S. But then come the newly revised penalties provisions: (4) CIVIL ACTION.In 5) CIVIL PENALTY. Further, S. 1096 specifically permits the FTC to continue to use its administrative process to determine that a company has violated the new rules on settlements.

Consulting 59

Consulting Manufacturing Referral IT 59

FDA Law

JANUARY 8, 2023

The Act requires DEA, in consultation with HHS, to assess annually whether an adequate and uninterrupted supply, down to specific strains, exists and to establish sufficient quotas to ensure an uninterrupted supply. We discuss the statute’s major provisions summarized below. Federal Research. Adequate and Uninterrupted Supply of Cannabis.

Medical 64

Medical Manufacturing Electronics Provider 64

FDA Law

JUNE 30, 2024

Lenz brings a wealth of experience, having provided consulting to medical device and combination product manufacturers on a wide range of pre and postmarket regulatory topics. Lenz, a highly esteemed Principal Medical Device Regulatory Expert at HPM will lead the session.

Medical 52

Medical Consulting Manufacturing Provider 52

FDA Law

JUNE 14, 2023

According to Dr. Shuren, the TAP Advisor acts as a consultant, engaging with companies to identify key questions, challenges, and areas requiring strategic problem-solving. While that observation is intended as praise for the TAP Pilot, it can be considered a sad commentary on the general state of manufacturer-CDRH interactions.)

Manufacturing 45

Manufacturing Medical Appointment Patient-Centered 45

FDA Law

AUGUST 21, 2023

Specifically, the Court explained, because “[t]he Pregnancy Warning Regulation simply does not speak to whether a further warning related to a drug’s use during pregnancy can be added to the general Pregnancy Warning on a drug label, whether added by the FDA or added by a manufacturer,” the ”regulation does not, therefore, preempt state law.”

Manufacturing 40

Manufacturing Consulting Healthcare Professional Vaccination 40

FDA Law

JUNE 10, 2025

Special Surveillance List of Chemicals, Products, Materials and Equipment Used in the Manufacture of Controlled Substances and Listed Chemicals, 90 Fed. Updating the list, DEA consulted law enforcement officials, forensic laboratory authorities, intelligence groups, drug signature and profiling programs, and international organizations.

Specialization 69

Specialization Manufacturing Electronics PCP 69

FDA Law

JANUARY 24, 2024

That’s a pretty lofty API manufacturing goal, but one that the API Innovation Center (“APIIC”) was charged to take up, consider, and propose some possible solutions. Biotechnology and Biomanufacturing; Harnessing Research and Development to Further Societal Goals.” bioeconomy.” The first goal under Theme 1—Goal 1.1—is

Supply Chain 69

Supply Chain Manufacturing Government Provider 69

FDA Law

SEPTEMBER 16, 2022

While it is not clear what HHS will discuss in its report, the FDA/CDER Emerging Technology Program and FDA/CBER Advanced Technologies Program are collaborative programs where industry, innovators/developers, and the FDA can discuss advanced technologies, including advanced manufacturing.

Supply Chain 75

Supply Chain Manufacturing Engineering Consulting 75